Tags : HIV

Merck Signs an Exclusive Agreement with Dewpoint Therapeutics to Develop

Shots: Dewpoint to receive up to $305M as up front and milestone along with royalties on sales of any approved product emerges under the collaboration The collaboration leverages Dewpoint’s biomolecular condensate platform to develop an HIV drug candidate with a unique mechanism, providing the potential to cure rather than suppressing the infection Biomolecular condensates are […]Read More

Gilead Signs a License Agreement with Xencor for its GS-9722

Shots: Xencor to receive upfront, milestones and royalties on successful development and commercialization of product. Gilead to get exclusive license rights for GS-9722 & up to three additional anti-HIV Abs and will be responsible for research, development, regulatory and commercial activities and all costs Gilead will get rights to access Xencor’s Xtend extended half-life and […]Read More

Thermo Fisher to Expand its Clinical Trials Capabilities and Collaborates

Shots: Thermo Fisher expands its clinical trials supply and distribution services network in China with the investment of $4.4M in its Suzhou facility to support the growth of clinical studies and to provide biotech companies with the resources to develop and commercialize new therapies in China Additionally, Thermo Fisher collaborates with Frontier to expedite the […]Read More

BioNTech Signs an Agreement with Gates Foundation to Develop Therapies

Shots: Gates Foundation to fund $55M which may extend up to $100M for the development of preclinical vaccine and immunotherapy candidates preventing HIV and tuberculosis infection. BioNTech will retain rights to commercialize candidates in developed countries while providing affordable access to the candidates in developing countries The agreements will further expand the BioNTech’s infectious disease […]Read More

Gilead Signs an Exclusive Worldwide License Agreement with Durect for

Shots: Durect to receive $25M up front, ~$145M milestones including ~$75M for development & regulatory and ~$70M on sales plus royalties on sales of products. Gilead to get exclusive WW rights to develop and commercialize a long-acting injectable HIV product based on Durect’s SABER technology Gilead also has an exclusive right to access Durect’s SABER […]Read More

ViiV Healthcare Initiates CUSTOMIZE Study of Dual-Drug Injectable Regimen for

Shots: The CUSTOMIZE study will evaluate the two-drug regimen consisting ViiV’s Cabotegravir and Janssen’s Edurant (rilpivirine) in patients with HIV with suppressed viral load and no resistance to cabotegravir or rilpivirine In Apr’2019, the US FDA has accepted NDA filing of long-acting dual-drug injectable regimen and has granted PR to NDA with its expected PDUFA […]Read More